Table 1.
Open and Recently Completed Clinical Trials for Pediatric Cancers Employing Monoclonal Antibodies and Immunocytokines that may involve NK-mediated mechanisms
| Clinical Trial Number | Title | Sponsor |
|---|---|---|
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | National Cancer Institute |
| NCT01598454 | Use of Racotumomab in Patients With Pediatric Tumors Expressing N- glycolylated Gangliosides | Laboratorio Elea S.A.C.I.F. y A. |
| NCT01595048 | Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia | Children’s Oncology Group |
| NCT01279707 | Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) | Queen Mary University of London |
| NCT01900496 | Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | Sidney Kimmel Comprehensive Cancer Center |
| NCT01552434 | Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab | M.D. Anderson Cancer Center |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | National Cancer Institute |
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma | National Cancer Institute |
| NCT01711554 | Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | National Cancer Institute |
| NCT01526603 | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | Masonic Cancer Center, University of Minnesota |
| NCT01419834 | Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors | Memorial Sloan-Kettering Cancer Center |
| NCT01662804 | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | Memorial Sloan-Kettering Cancer Center |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | Memorial Sloan-Kettering Cancer Center |
| NCT01183429 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | Memorial Sloan-Kettering Cancer Center |
| NCT01757626 | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | Memorial Sloan-Kettering Cancer Center |
| NCT01183897 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow | Memorial Sloan-Kettering Cancer Center |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | Memorial Sloan-Kettering Cancer Center |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | Memorial Sloan-Kettering Cancer Center |
| NCT01704716 | High Risk Neuroblastoma Study 1 (1.5) of SIOP-Europe (SIOPEN) | St. Anna Kinderkrebsforschung, Austria |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) (LTI) | St. Anna Kinderkrebsforschung, Austria |
| NCT01576692 | A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma (GD2NK) | St. Jude Children's Research Hospital |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | St. Jude Children's Research Hospital |
| NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | St. Jude Children's Research Hospital |
| NCT01592045 | Ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | United Therapeutics |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Morphotek |
| NCT01334515 | Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | COG |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | aaaaaaaaaCOG |